Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

98
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
98
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

76
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

56
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
56
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

77
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
77
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

67
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
67
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

79
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
79

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in Medicaid Administrative Expenditures During the COVID-19 Public Health Emergency.

Inquiry : a journal of medical care organization, provision and financing·2026
Same author

DigitAb: Domain-Adaptive Cell Type Prediction Method from Light Microscopy Images.

bioRxiv : the preprint server for biology·2026
Same author

Spatially Resolved Banff Tubulitis and Glomerulitis Scoring in Kidney Allograft Biopsies via Artificial Intelligent -Based Structure Segmentation and Spatial Transcriptomics.

bioRxiv : the preprint server for biology·2026
Same author

A Large, Diverse, Urban Cardiovascular Health e-Cohort in Childhood and Adolescence: Protocol for the Young Hearts Study.

JMIR research protocols·2026
Same author

Not all reference samples are equal in single-cell transcriptomics of human kidney tissue.

JCI insight·2026
Same author

A transcriptional patient map of systemic lupus erythematosus reveals disease-related multicellular immune programs conserved between blood and kidney.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Mar 7, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K

Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.

Marc B Rosenman1, Brian Decker2, Kenneth D Levy2

  • 1Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA; Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|February 19, 2017
PubMed
Summary
This summary is machine-generated.

Implementing pharmacogenomics programs in diverse patient populations presents challenges in education, technology integration, and workflow. Addressing these is key for successful precision medicine adoption in safety-net health systems.

Keywords:
clinical decision supportelectronic health recordspharmacogenomicsprecision medicine

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.6K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K

Related Experiment Videos

Last Updated: Mar 7, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.6K
Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
07:15

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation

Published on: January 16, 2019

11.5K

Area of Science:

  • Genomic Medicine
  • Health Services Research
  • Implementation Science

Background:

  • Precision medicine initiatives require robust program implementation strategies.
  • The Indiana GENomics Implementation: an Opportunity for the Underserved (INGenious) program at Eskenazi Health serves as a case study.
  • This program focuses on implementing a panel of genomic tests within a safety-net health care system.

Purpose of the Study:

  • To describe the challenges and potential solutions encountered during the implementation of a large-scale pharmacogenomics program.
  • To provide insights for other health care systems implementing similar precision medicine initiatives.

Main Methods:

  • A descriptive case study approach was used to analyze the INGenious program.
  • The study encompassed a pharmacogenomics program with 14 genes and 27 medications.
  • The diverse patient population included individuals with multiple chronic illnesses at an urban safety-net hospital.

Main Results:

  • Key implementation challenges were categorized into patient/clinician education, technology integration, translational science, regulatory/reimbursement issues, and outcome measurement.
  • Workflow considerations were a critical cross-cutting theme.
  • Distinctive challenges included managing patients with multiple chronic illnesses and pharmacogenomics-relevant medications, and patient recruitment/follow-up.

Conclusions:

  • Implementing large-scale health care innovations is inherently challenging.
  • Sharing implementation experiences and adopted solutions can inform future precision medicine endeavors.
  • The findings offer valuable insights for researchers and practitioners in diverse health care settings.